ERBB2 and breast cancer: Patients who exhibited a greater degree of TI HER2 trogocytosis achieved a greater degree of HER2 trogocytosis following HER2+ breast cancer cell targeting by trastuzumab, resulting in these patients experiencing more trastuzumab-mediated ADCC.